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Purpose:  Due  to  its  ability  to  disrupt  transforming  growth  factor  beta  (TGF-β)  signaling,  halofuginone  has  been
successfully used to treat various fibrotic disorders. Here we investigated the antifibrotic potential of halofuginone in
human corneal fibroblasts.
Methods: Human corneal fibroblasts were isolated from human donor corneas for in vitro experiments. TGF-β was used
to stimulate pro-fibrotic responses from corneal fibroblasts under halofuginone treatment. The expression of alpha smooth
muscle actin (α-SMA) and fibronectin was analyzed by western blots. Phalloidin toxin was used to stain cultures for stress
fiber assemblies. Quantitative reverse transcription PCR (qRT–PCR) and immunostaining were used to analyze the
expression of type I collagen mRNA and protein, respectively. The expression of Smad2, Smad3, phospho-Smad2, and
phospho-Smad3 was determined by western blots.
Results: Halofuginone was well tolerated by human corneal fibroblasts up to 10 ng/ml as demonstrated by a cell viability
assay. At this concentration, TGF-β-induced expression of the fibrotic markers α-SMA, fibronectin, and type I collagen
was significantly reduced. Interestingly, under our experimental conditions, halofuginone treatment led to reduced protein
expression of Smad3, which was both dose- and time-dependent.
Conclusions: Our results suggest that halofuginone may exert its antifibrotic effects in the cornea via a novel molecular
mechanism and may be used as an antifibrotic agent for corneal fibrosis treatment.
Fibrotic disorders affect all tissues and organs. Although
fibrosis  is  an  important  tissue  repair  mechanism,  it  can
negatively impact the integrity of a tissue if it progresses
excessively. The fibrotic process involves multiple signaling
pathways,  which  activate  myofibroblast  transformation,
fibrotic marker expression, and extracellular matrix (ECM)
protein  deposits.  Among  these  pro-fibrotic  signaling
pathways, transforming growth factor beta (TGF-β) is likely
the most important as demonstrated by in vitro experiments
and animal models [1-3]. The TGF-β signal is transduced
through TGF-β receptor type I (TβR-I, also known as ALK5)
and type II (TβR-II, a serine/threonine protein kinase) [4,5].
Binding of TGF-β induces the association of TβR-I and TβR-
II, allowing TβR-II to phosphorylate the GS domain of TβR-
I. Essential downstream effectors, including Smad proteins
and  mitogen-activated  protein  kinase  (MAPK),  are  then
activated  by  the  phosphorylated  receptor  complex  [6].  In
Smad signaling, the phosphorylated receptor complex recruits
receptor-regulated  Smad  proteins  (R-Smad),  including
Smad2 and Smad3, and activates them by phosphorylation.
The  activated  R-Smads  form  heterodimers  and  further
complex with Smad4 (Co-Smad), then translocate into the
nucleus to regulate transcription. Other non-Smad signaling
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pathways,  including  Rho/Rho-associated  protein  kinase
(ROCK), MAP kinases, phosphatase 2A, signal transducers
and  activators  of  transcription/nuclear  factor  kappa-B
(NFκB), and phosphatidylinositol-3 kinase (PI3K)/Akt, can
also cross-talk with Smad signaling and therefore modulate
the fibrotic processes [7].
In corneal tissue, fibrosis following injuries and surgeries
or  resulting  from  disorders,  such  as  limbal  stem  cell
deficiency, can cause corneal opacity and scarring, thereby
compromising vision. Various researchers have confirmed the
essential role of TGF-β signaling in corneal fibrosis, and thus
vigorous investigation into preventing corneal fibrosis has
focused on strategies to disrupt this pathway [8]. For example,
overexpression  of  Smad7  by  a  gene  therapy  approach
significantly reduced corneal fibrosis in an animal model [8,
9]. Chemical inhibitors targeting various pathways (indicated
in parentheses), such as trichostatin A (histone deacetylase)
[10],  C3  transferase  or  Y27632  (Rho/ROCK)  [11],  and
pioglitazone  (peroxisome  proliferator-activated  receptor-
gamma) [12] have also shown great promise in inhibiting the
expression of fibrotic markers in vitro and/or suppressing
fibrosis in animal models.
Halofuginone  (7-bromo-6-chloro-3-[3-(3-hydroxy-2-
piperidinyl)-2-oxopropyl]-4(3H)-quinazolinone)  is  a
synthetic derivative of febrifugine, a plant alkaloid isolated
from the roots of Dichroa febrifuga. Halofuginone has been
used widely in the poultry industry for treating coccidiosis and
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479has  recently  been  applied  for  treating  fibrosis  and
neovascularization and for anti-tumor therapy [13-15]. Both
in vitro and animal studies have revealed that halofuginone
effectively inhibits type I collagen synthesis in many cell types
and tissues subjected to various injuries or stresses [16,17]. In
dermal  fibroblasts,  halofuginone  treatment  not  only
significantly reduces the production of type I collagen, but
also inhibits the expression of other fibrotic markers and ECM
proteins  [18].  The  transformation  of  fibroblasts  to
myofibroblasts  is  also  inhibited  by  halofuginone  [19].  In
experimental  animal  models  of  systemic  sclerosis  [20],
chronic graft-versus-host disease [21] and radiation damage
[22], halofuginone significantly reduces fibrosis, scarring and
inflammation. Halofuginone has been approved by the United
States Food and Drug Administration for treating scleroderma
(TempostatinTM;  Collgard  Biopharmaceutical  Ltd.,  Petah
Tikva, Israel).
The potent antifibrotic efficacy of halofuginone and its
long history of safe usage in veterinary and clinical fields have
prompted us to investigate its potential in preventing corneal
fibrosis.  Using  corneal  fibroblasts  isolated  from  human
donors,  we  have  demonstrated  that  halofuginone  has  low
cytotoxicity  but  high  potency  in  suppressing  the  fibrotic
markers alpha smooth muscle actin (α-SMA), fibronectin, and
type I collagen. Our results also indicate that halofuginone
exerts its antifibrotic effect in human corneal fibroblasts by
down-regulating Smad3 protein expression, which has not
been reported previously. Based on these preliminary results,
we  propose  that  halofuginone  bears  great  promise  for
ophthalmic  antifibrotic  applications  and  warrants  further
study in animal models.
METHODS
Human  corneal  fibroblast  cultures:  Human  corneal
fibroblasts  were  isolated  from  Institutional  Review  Board
exempt donor tissue obtained from the Minnesota Lions Eye
Bank  (Minneapolis,  MN).  Central  corneas  were  dissected
from donor cornea buttons for overnight collagenase digestion
[23]; collagenase I was purchased from Invitrogen (Carlsbad,
CA). The digested samples were passed through a cell strainer
to remove any pieces of undigested tissue, and cells were spun
down  and  rinsed  with  DMEM  (Invitrogen).  Cells  were
propagated in fibroblast medium, which consists of a basal
medium supplemented with 2% FBS, 1× fibroblast growth
supplement  and  antibiotics  and  which  is  formulated
specifically  for  the  optimal  growth  and  minimal
differentiation  of  fibroblasts  (ScienCell  Research
Laboratories, Carlsbad, CA). For halofuginone and TGF-β
experiments, cells from passages 3–6 were cultured in DMEM
supplemented with 10% FBS. Unless otherwise noted, cells
were seeded at a density of approximately 104 cells/cm2.
Cytotoxicity of halofuginone: Human fibroblasts were seeded
3,000 cells per well in 96-well plates and grown to 30%–40%
confluence.  Cells  were  then  treated  with  halofuginone
(Toronto Research Chemicals, North York, Ontario, Canada)
or  vehicle.  Twenty-four  hours  following  the  addition  of
halofuginone, 50 µM resazurin dye (Sigma-Aldrich, Saint
Louis, MO) was added, and cells were allowed to incubate
another 24 h. Resazurin fluorescence was then measured using
an  Fmax  plate  reader  and  instrument-specific  software,
SOFTmax  PRO  version  1.3.1  (Molecular  Devices,
Sunnyvale, CA). To determine baseline fluorescence, 0.1%
Triton X-100 was used to lyse cells.
Western blot experiments: For fibrotic marker experiments,
human corneal fibroblasts were treated for one hour with 10
ng/ml  halofuginone  before  adding  2  ng/ml  TGF-β  (Cell
Sciences, Canton, MA), and cell lysates were harvested at 48
h. For Smad signaling experiments, human corneal fibroblasts
were treated with 10 ng/ml halofuginone for 24 h, then 2 ng/
ml TGF-β was added, and cell lysates were harvested at 30
min. Lysates were separated on 12% SDS–PAGE gels then
transferred  onto  nitrocellulose  membranes.  Antibodies
against  fibrotic  markers  α-SMA  (clone  1A4)  and  human
fibronectin were purchased from Sigma-Aldrich, as well as
antibody  against  β-actin  (AC-15).  Antibodies  against
phospho-Smad3  (Ser423/425;  C25A9),  phospho-Smad2
(Ser465/467; 138D4), and Smad2 (L16D3) were purchased
from Cell Signaling Technology (Danvers, MA); and Smad3
(FL-425) and Smad7 (Z8-B) antibodies were purchased from
Santa  Cruz  Biotechnology  (Santa  Cruz,  CA).  Antibody
against GAPDH was purchased from Biodesign International
(Saco, ME). Secondary antibodies labeled with IRDye 700 or
IRDye 800 were purchased from Rockland Immunochemicals
Inc. (Gilbertsville, PA). An Odyssey Infrared Imaging System
(Li-Cor Biosciences, Lincoln, NE) was used to image protein
bands, and included analysis software was used to digitize and
convert data. Data were normalized to β-actin.
qRT–PCR: Human corneal fibroblasts were treated for 1 h
with 10 ng/ml halofuginone before the addition of 2 ng/ml
TGF-β.  Forty-eight  hours  after  adding  TGF-β,  cells  were
lysed and total RNA was collected using an RNeasy Mini Kit
(QIAGEN Inc., Valencia, CA); genomic DNA was digested
with RNase-free DNase I (QIAGEN). Total RNA (5 µg) was
then reverse transcribed using SuperScript III First Strand
Synthesis  System  (Invitrogen).  Quantitative  reverse
transcription  PCR  (qRT-PCR)  was  performed  using  an
iCycler thermal cycler (Bio-Rad Laboratories, Inc., Hercules,
CA) with iQ SYBR Green Supermix (Bio-Rad Laboratories)
and primers for type I collagen alpha 2 (COL1A2; F, 5′-GCA
CAT GCC GTG ACT TGA GA-3′; R, 5′-CAT CCA TAG
TGC ATC CTT GAT TAG G-3′) [24] and β-actin (ACTB; F,
5′-CTG GCA CCC AGC ACA ATG-3′; R, 5′-AGC GAG
GCC  AGG  ATG  GA-3′)  [25].  Thirty-five  amplification
cycles, consisting of 10 s at 95 °C and 30 s at 56 °C, were run
on  25  µl  reactions.  A  standard  curve  to  determine  the
amplification efficiency (E) of each primer pair was generated
from a series of cDNA log dilutions, where E=10-1/slope of standard
curve.  An  iQ5  real-time  PCR  detection  system  and
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Laboratories) were used to collect and analyze real-time PCR
data; the fold change expression of COL1A2 mRNA was
normalized to ACTB mRNA by the Pfaffl method, taking into
account the actual amplification efficiency of primer pairs.
Immunostainings  and  phalloidin  toxin  staining:  Human
corneal  fibroblasts  were  seeded  in  glass  8-well  chamber
slides, then treated for 1 h with 10 ng/ml halofuginone before
adding 2 ng/ml TGF-β. Forty-eight hours after the addition of
TGF-β,  cells  were  fixed  in  4%  paraformaldehyde.  For
detection of type I collagen, cells were blocked with 10%
rabbit normal serum in 1× PBS plus 0.02% Tween-20 then
stained  with  rabbit  anti-type  I  collagen  antibody  (1:20;
Southern Biotech, Birmingham, AL) overnight at 4 °C. A
rabbit anti-goat Alexa Fluor 488 (1:1,000; Invitrogen) was
used as the secondary antibody. For phalloidin staining, cells
were permeablized with 1% Triton X-100 following fixation,
blocked in 1% BSA in 1× PBS, then incubated in Alexa Fluor
594  phalloidin  toxin  (1:40;  Invitrogen).  Nuclei  were
counterstained with Hoechst’s dye 33342. Cells were imaged
with a Zeiss Axiovert 200M epi-fluorescent microscope (Carl
Zeiss, Jena, Germany).
Luciferase assay: Plasmids p3TP-Lux (a generous gift from
Dr.  Joan  Massague,  Memorial  Sloan-Kettering  Cancer
Center, New York, NY) and pRL (Promega, Madison, WI)
were transfected into human corneal fibroblasts with Fugene
Figure  1.  Halofuginone  is  nontoxic  at  low  concentrations.  The
viability of human corneal fibroblasts treated with halofuginone is
similar to control for concentrations of 10 ng/ml or less. The viability
of  cells  treated  with  50  ng/ml  or  100  ng/ml  halofuginone  is
significantly decreased compared to control (* p<0.005). Viability is
expressed as fluorescence intensity of metabolized resazurin relative
to control (n=5, bar=S.E.M.).
6 (Roche Applied Science, Indianopolis, IN) according to the
manufacturer’s instructions. p3TP-Lux contains the firefly
luciferase gene whose expression is driven by a synthetic
promoter containing three tandem repeats of the activator
protein-1 binding motif and part of the plasminogen activator
inhibitor-1 promoter, which is activated by Smad3 binding
[26]; the Renilla luciferase encoded by pRL is constitutively
expressed. Ten ng/ml halofuginone was added to cells 4 h after
transfection,  and  2  ng/ml  TGF-β  was  added  24  h  after
transfection. Twenty-four hours after the addition of TGF-β
(48  h  after  transfection),  cell  lysates  were  harvested  and
assayed with a Dual-Luciferase Reporter System Assay kit
(Promega); the luciferase activity of lysates was measured
with a Lumat LB 9507 Luminometer (Berthold, Germany).
The  respective  activity  of  firefly  luciferase  and  Renilla
luciferase were measured sequentially from a single sample,
and the ratio of reporter firefly luciferase to control Renilla
luciferase was used for comparison.
RESULTS
Cytotoxicity  of  halofuginone  in  corneal  fibroblasts:  To
determine the suitable treatment dosage of halofuginone, we
assayed resazurin metabolism of human corneal fibroblasts
treated  with  varying  halofuginone  concentrations.
Halofuginone  concentrations  up  to  10  ng/ml  showed  no
significant toxicity compared to vehicle (Figure 1). However,
at  higher  concentrations  of  50  ng/ml  and  100  ng/ml,
halofuginone resulted in significantly decreased cell viability.
Therefore, 10 ng/ml was chosen as the treatment dose for
subsequent experiments.
Halofuginone  suppresses  expression  of  α-SMA  and
fibronectin in corneal fibroblasts: In the fibrotic process, α-
SMA and fibronectin are known to increase significantly in
fibroblasts and have been commonly used as fibrotic markers.
Western  blot  analysis  confirmed  that  TGF-β  treatment
increased the expression of α-SMA and fibronectin in human
corneal fibroblast cultures compared to no treatment (Figure
2A).  Halofuginone  treatment  suppressed  TGF-β-induced
expression of α-SMA and fibronectin, as well as reduced the
basal  level  of  α-SMA  (Figure  2A).  Results  from  four
independent experiments are summarized in Figure 2B.
Halofuginone  inhibits  stress  fiber  assembly  in  corneal
fibroblasts: Because α-SMA is a component of stress fibers,
we  investigated  stress  fiber  assembly  in  human  corneal
fibroblasts  by  staining  with  fluorescent-labeled  phalloidin
toxin; we confirmed the positive regulation of stress fiber
assembly by TGF-β (Figure 2C). In contrast, phalloidin toxin
staining of cells co-treated with halofuginone was not only
significantly less than the staining of cells treated with TGF-
β alone, but was also similar to the staining of the untreated
control (Figure 2C).
Halofuginone inhibits type I collagen expression in corneal
fibroblasts: We also investigated the effect of halofuginone
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481Figure  2.  Halofuginone  suppresses
TGF-β-induced  expression  of  fibrotic
markers and stress fiber assemblies in
human  corneal  fibroblasts.  A:
Representative  western  blots  show
increased  expression  of  α-SMA  and
fibronectin (FN) after TGF-β treatment
and inhibition of the induced expression
by halofuginone (Hal). β-actin shown as
loading control. B: Quantification and
normalization  of  α-SMA  and
fibronectin western blot data. * p<0.05
compared  to  control,  **  p<0.05
compared to TGF-β (n=4, bar=S.E.M.).
C: Representative images of phalloidin
toxin staining show cells treated with
TGF-β  (top  right)  display  greater
fluorescence  signal  than  untreated
control (top left) or cells treated with
TGF-β and halofuginone (lower right).
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482on the expression of another ECM protein and classic fibrotic
marker, type I collagen. Human corneal fibroblasts co-treated
with  halofuginone  and  TGF-β  displayed  much  weaker
immunostaining  signals  for  type  I  collagen  than  cells
stimulated with TGF-β alone and weaker signals than the
untreated  control  (Figure  3A).  Analysis  by  qRT–PCR
corroborated immunostaining results: treatment with TGF-β
stimulated  the  expression  of  COL1A2  mRNA,  and
halofuginone was able to attenuate this upregulation, as well
as to suppress basal COL1A2 mRNA expression (Figure 3B).
Halofuginone exerts its inhibitory effects via down-regulation
of Smad3 expression: After 24-h treatment with halofuginone,
we observed the down-regulation of Smad3 protein in human
corneal fibroblasts (Figure 4A). When normalized to β-actin,
Smad3  protein  in  cells  treated  with  halofuginone  is
significantly less than in either the untreated control or in cells
treated only with TGF-β (Figure 4B, upper left panel). In cells
treated  with  halofuginone  and  TGF-β,  the  ratio  of
phosphorylated  Smad3  protein  to  total  Smad3  protein  is
comparable  to  the  ratio  in  cells  treated  only  with  TGF-β
Figure  3.  Halofuginone  suppresses
TGF-β-induced  expression  of  type  I
collagen protein and mRNA in human
corneal  fibroblasts.  A:  Representative
images of immunostainings for type I
collagen  show  cells  treated  with
halofuginone (Hal) and TGF-β (bottom
right)  display  similar  fluorescence
signal  as  untreated  control  cells  (top
left), but less signal than cells treated
with TGF-β only (top right). B: qRT–
PCR  analysis  demonstrates  treatment
with halofuginone significantly reduces
both  TGF-β-induced  expression  and
basal  expression  of  COL1A2  mRNA
(normalized to ACTB mRNA). * p<0.05
compared  to  control,  **  p<0.05
compared to TGF-β (n=4, bar=S.E.M.).
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483(Figure 4B, upper right panel). On the other hand, neither the
phosphorylation  nor  the  expression  of  Smad2  was
significantly  affected  by  halofuginone  (Figure  4B,  lower
panels). Figure 4B summarizes results from three independent
experiments. The observed effect of halofuginone on total
Smad3  expression  is  both  dose-  and  time-dependent:
significant reduction of Smad3 protein is observed only at
concentrations of 5 ng/ml or greater (Figure 4C) and only after
Figure 4. Halofuginone treatment down-
regulates Smad3 protein expression but
not relative Smad3 phosphorylation in
human  corneal  fibroblasts.  A:
Representative  western  blots  show
halofuginone  (Hal)  reduces  Smad3
protein  expression.  While  Smad2
phosphorylation  (P-Smad2)  is  not
affected by halofuginone, the intensity
of  phosphorylated  Smad3  (P-Smad3)
signal  decreases  significantly.  β-actin
and  GAPDH  shown  as  simultaneous
loading controls. B: Quantification and
normalization  of  Smad2,  phospho-
Smad2,  Smad3,  and  phospho-Smad3
western blot data. * p<0.05 compared to
control, ** p<0.05 compared to TGF-β
(n=3, bar=S.E.M.). C: Dose-dependent
down-regulation of Smad3 protein by
halofuginone treatment for 24 h before
addition of TGF-β. D: Time-dependent
down-regulation of Smad3 protein by
10 ng/ml halofuginone treatment.
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484treatment of 4 h or longer, the greatest effect being seen at 24
h (Figure 4D).
Halofuginone  reduces  reporter  luciferase  activity  in
transfected  corneal  fibroblasts:  Because  we  found
halofuginone to decrease Smad3 expression but not relative
Smad3  phosphorylation  (Figure  4),  we  investigated
endogenous  Smad3-related  transcriptional  activity  using  a
luciferase reporter plasmid, p3TP-Lux. We confirmed that
TGF-β treatment significantly increases reporter luciferase
activity,  as  normalized  to  control  luciferase  activity,  in
transfected human corneal fibroblasts (Figure 5). Treatment
with halofuginone significantly inhibits this upregulation of
reporter luciferase activity, as well as significantly decreases
basal reporter luciferase activity in cells not treated with TGF-
β (Figure 5).
DISCUSSION
Smad3  is  a  key  mediator  of  the  TGF-β-depedent  fibrotic
response [27]. Smad3 signaling has become a promising target
for antifibrotic therapies [8], and both genetic and chemical
approaches  have  been  developed  to  disrupt  this  pathway.
Among the chemical agents able to inhibit Smad3 potently,
halofuginone is one of the few being studied extensively in
humans as well as in animals. However, to our knowledge, the
antifibrotic  effects  of  halofuginone  on  cultured  corneal
fibroblasts  or  on  the  intact  cornea  have  not  been  studied
previously.  Here  we  report  halofuginone  suppresses  the
expression of fibrotic markers and ECM proteins in cultured
human corneal fibroblasts; using a variety of techniques, we
demonstrated  that  halofuginone  treatment  significantly
reduces the TGF-β-induced expression of fibronectin, α-SMA
and type I collagen and formation of stress fiber assemblies
(Figure 2 and Figure 3). Based on these findings and its low
toxicity on corneal fibroblasts (Figure 1), halofuginone may
serve as a promising candidate for reducing corneal fibrosis
and haze and restoring vision in patients with corneal injuries
or disorders.
These results, i.e., significantly reduced expression of
fibrotic  markers  and  ECM  proteins  by  halofuginone,  are
consistent with halofuginone studies on fibroblasts from other
tissues,  e.g.  from  skin.  Our  results  also  indicate  that,  in
cultured  corneal  fibroblasts,  the  suppression  of  fibrotic
markers and ECM proteins by halofuginone may be mediated
by the down-regulation of Smad3 protein expression, which
has  not  been  reported  previously  to  our  knowledge.  This
reduced Smad3 protein expression is accompanied by less
total phosphorylated Smad3 upon TGF-β stimulation (Figure
4A), which may account for the observed decrease in Smad3-
related transcriptional activity as demonstrated by the p3TP-
Lux luciferase reporter assay (Figure 5). The observed effect
on Smad3 protein expression is dose-dependent (Figure 4C)
and most prominent at 24-h treatment (Figure 4D), but can be
reversed by withdrawing halofuginone treatment (data not
shown).
Our Smad3 results are in contrast to previous reports,
which do not report down-regulation of total Smad3 protein
but  instead  indicate  that  halofuginone  disrupts  Smad3
phosphorylation. Halofuginone pretreatment ranging from 30
min  to  24  h  inhibits  TGF-β-induced  phosphorylation  of
Smad3  in  other  cell  types  [18,22,28,29],  abolishing
downstream  transcriptional  activity.  For  example,
phosphorylated Smad3 binds directly to the promoter region
of the COL1A2 gene to activate transcription in embryonic
mouse dermal fibroblasts; and halofuginone treatment, by
specifically  suppressing  the  phosphorylation  of  Smad3,
reduces the expression of type I collagen [18]. Because TβR-
II phophorylates the MH2 domains of both Smad2 and Smad3
indiscriminately,  such  a  specific  effect  on  Smad3
phosphorylation  may  be  mediated  via  post-Smad
phosphorylation regulation as proposed by McGaha et al. and
Roffe et al. [18,29]. Although one-hour pretreatment with
halofuginone effectively suppresses expression of α-SMA,
fibronectin,  and  type  I  collagen  in  our  human  corneal
fibroblasts (Figures 2 and 3), one-hour pretreatment did not
inhibit  TGF-β-induced  phosphorylation  of  Smad3  in  our
hands (data not shown). We did observe less phosphorylated
Figure  5.  Halofuginone  suppresses  Smad3-related  transcriptional
activity in transfected human corneal fibroblasts. Transfected cells
treated with TGF-β display significantly greater reporter luciferase
activity  than  untreated  control  cells,  and  halofuginone  (Hal)
significantly inhibits this induced reporter activity. Halofuginone
also reduces basal reporter luciferase activity. Reporter luciferase
activity expressed as firefly activity (from p3TP-Lux) relative to
Renilla  luciferase  activity  (from  pRL).  Results  from  three
independent experiments are shown. * p<0.05 compared to control,
** p<0.05 compared to TGF-β (n=3, bar=S.E.M.).
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485Smad3 after 24-h pretreatment with halofuginone; however,
since we found this decrease was proportional to the observed
decrease in total Smad3 (Figure 4B), we believe halofuginone
may act via a novel mechanism in corneal fibroblasts which
involves modulation of Smad3 expression.
The  underlying  mechanism  by  which  halofuginone
down-regulates Smad3 protein expression in human corneal
fibroblasts  awaits  further  investigation.  Halofuginone  has
been shown to upregulate the expression of Smad7 and down-
regulate the expression of TβR-II, which in combination lead
to the inactivation of Smad2 and Smad3 signaling in various
mouse WT and knockout fibroblasts [22]. While western blots
showed that halofuginone did not alter the protein expression
of either Smad7 (data not shown) or Smad2 (Figure 4B) in our
corneal fibroblasts, potential changes in TβR-II expression
may be involved and warrant future experiments. A recent
study has shown that halofuginone exerts its anti-proliferative
effects in an acute promyelocytic leukemica cell line, NB4,
by upregulating the expression of Smad3, as well as other
TGF-β signaling molecules [30]; it is worth noting, however,
that  the  effective  concentrations  were  significantly  higher
(75–200 ng/ml) compared to the dose used in our corneal
fibroblast study (10 ng/ml). Other signaling pathways may
also regulate the protein expression of Smad3: one study on a
mouse epithelial cell line proposed the NFκB and/or nitric
oxide  synthase  pathways  as  mediators  of  reduced  Smad3
protein expression and altered TGF-β signaling resulting from
the  overexpression  of  a  regulatory  domain  of  the  cystic
fibrosis transmembrane conductance regulator [31].
TGF-β signaling is highly dependent on the cell type and
cell  signaling  context.  For  example,  corneal  fibroblasts
isolated from Smad3 knockout mice fail to transform into
myofibroblasts  under  TGF-β  treatment,  whereas  dermal
fibroblasts with Smad3 deficiency retain the capability of
myofibroblast  transformation  [32,33].  However,  while
Smad3 knockout dermal fibroblasts express less fibronectin
than wild-type dermal fibroblasts upon stimulation with TGF-
β  [2],  this  induced  fibronectin  expression  is  not  different
between  Smad3  heterozygous  knockout  and  Smad3
homozygous knockout corneal fibroblasts [33]. Furthermore,
studies on transgenic animals and cultured fibroblasts in vitro
show that, although similar in many aspects, the cutaneous
and corneal wound healing processes are distinct in regards to
the  regulation  of  TGF-β  production,  the  response  of
inflammatory cells to TGF-β, and the expression of fibrotic
markers  [2,33].  Corneal  fibroblasts  may  respond  to
halofuginone differently due to their unique features in TGF-
β signaling and the fibrotic process.
In addition to disrupting Smad3 signaling, halofuginone
has  also  been  found  to  activate  the  PI3K/Akt  and  ERK
pathways in muscle cells [29], activate c-Jun signaling in
mouse  embryonic  fibroblasts  [18],  inhibit  NFκB  and  p38
MAPK in activated T cells [34], and activate NFκB and p38
MAPK in hepatic stellate cells [35]. As indicated by the above
reports and our results, the effects of halofuginone may be
highly dependent on the cell type and/or the cellular signaling
context.  Because  halofuginone  seems  to  affect  distinct
signaling pathways in different cell and tissue types, it may
be desirable to avoid systemic administration of halofuginone;
for antifibrotic applications, a cell- or tissue-specific delivery
method may be needed instead to minimize unwanted side
effects.
In summary, data from the present study suggest that
halofuginone  has  the  potential  to  mitigate  the  deleterious
effects  of  corneal  fibrosis.  Our  findings  present  a  new
opportunity for managing fibrosis of the ocular surface by
down-regulating  Smad3.  Future  investigations  will  better
establish the signaling pathway through which halofuginone
exerts its effects and will examine whether these in vitro
results translate to in vivo efficacy.
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